(Reuters) – Canadian Pacific Railway Ltd (CP) said on Saturday it filed a formal objection with a U.S. regulator stating Canadian National Railway Co’s near $30 billion rival bid for Kansas City Southern does not qualify to be exempted from tougher merger rules.
Last week, the U.S. Surface Transportation Board (STB) granted waiver to CP’s $25 billion agreed bid for Kansas City Southern, which means the deal would not be subjected to the tougher railroad merger rules the regulator put in place in 2001.
CP won the exemption based on its smaller size and analysts and shareholders have said that STB’s ruling reduces the regulatory risk to CP’s deal.
CP and larger rival Canadian National (CN) are in race to take over U.S. railroad Kansas City Southern (KCS), which would create the first direct railway linking Canada, U.S. and Mexico.
Either combination is seeking to benefit from the expected pick up in trade after the US-Mexico-Canada Agreement was ratified last year.
In its argument filed with the regulator on Friday, CP said CN’s offer to acquire KCS should be cause for concern because of its size.
“A combined CN/KCS would greatly expand the size of the fifth largest U.S. Class 1 railroad, vastly increasing the gap between CN/KCS and … CP,” Canadian Pacific said.
CN and KCS did not immediately respond to a request for comment on CP’s filing to the regulator.
CN launched an unsolicited cash-and-stock offer valuing KCS at about $29.55 billion, after CP agreed to buy KCS for about $25 billion in March.
CP has previously said it was not considering to raise its offer. KCS previously said its board has determined that CN’s competing offer could be expected to lead to a “superior proposal.”
(Reporting by Shubham Kalia in Bengaluru; editing by Diane Craft)
COVID-19 booster shots could rake in billions for some vaccine makers – Global News
Billions more in profits are at stake for some vaccine makers as the U.S. moves toward dispensing COVID-19 booster shots to shore up Americans’ protection against the virus.
How much the manufacturers stand to gain depends on how big the rollout proves to be.
Exactly who should get a booster was a contentious decision as advisers to the Centers for Disease Control and Prevention spent two days this week poring over the evidence. CDC director Dr. Rochelle Walensky endorsed most of their choices: People 65 and older, nursing home residents and those ages 50 to 64 who have chronic health problems such as diabetes should be offered one once they’re six months past their last Pfizer dose. Those 18 and older with health problems can decide for themselves if they want a booster.
Still, the crisis is constantly evolving, and some top U.S. health officials expect boosters will be more broadly authorized in the coming weeks or months. And that, plus continued growth in initial vaccinations, could mean a huge gain in sales and profits for Pfizer and Moderna in particular.
U.S. FDA, CDC support Pfizer-BioNTech boosters for people high-risk or aged 65+
“The opportunity quite frankly is reflective of the billions of people around the world who would need a vaccination and a boost,” Jefferies analyst Michael Yee said.
Wall Street is taking notice. The average forecast among analysts for Moderna’s 2022 revenue has jumped 35% since President Joe Biden laid out his booster plan in mid-August.
Most of the vaccinations so far in the U.S. have come from Pfizer, which developed its shot with Germany’s BioNTech, and Moderna. They have inoculated about 99 million and 68 million people, respectively. Johnson & Johnson is third with about 14 million people.
Immunocompromised offered vaccine booster shot. Who is eligible?
No one knows yet how many people will get the extra shots. But Morningstar analyst Karen Andersen expects boosters alone to bring in about $26 billion in global sales next year for Pfizer and BioNTech and around $14 billion for Moderna if they are endorsed for nearly all Americans.
Those companies also may gain business from people who got other vaccines initially. In Britain, which plans to offer boosters to everyone over 50 and other vulnerable people, an expert panel has recommended that Pfizer’s shot be the primary choice, with Moderna as the alternative.
Andersen expects Moderna, which has no other products on the market, to generate a roughly $13 billion profit next year from all COVID-19 vaccine sales if boosters are broadly authorized.
WHO calls out rich countries for ‘empty promises’ COVID-19 vaccine donations for poor nations
Potential vaccine profits are harder to estimate for Pfizer, but company executives have said they expect their pre-tax adjusted profit margin from the vaccine to be in the “high 20s” as a percentage of revenue. That would translate to a profit of around $7 billion next year just from boosters, based on Andersen’s sales prediction.
J&J and Europe’s AstraZeneca have said they don’t intend to profit from their COVID-19 vaccines during the pandemic.
For Pfizer and Moderna, the boosters could be more profitable than the original doses because they won’t come with the research and development costs the companies incurred to get the vaccines on the market in the first place.
WBB Securities CEO Steve Brozak said the booster shots will represent “almost pure profit” compared with the initial doses.
Drugmakers aren’t the only businesses that could see a windfall from delivering boosters. Drugstore chains CVS Health and Walgreens could bring in more than $800 million each in revenue, according to Jeff Jonas, a portfolio manager with Gabelli Funds.
Dr. Bogoch weighs in on mandatory vaccines & booster shots
Jonas noted that the drugstores may not face competition from mass vaccination clinics this time around, and the chains are diligent about collecting customer contact information. That makes it easy to invite people back for boosters.
Drugmakers are also developing COVID-19 shots that target certain variants of the virus, and say people might need annual shots like the ones they receive for the flu. All of that could make the vaccines a major recurring source of revenue.
The COVID-19 vaccines have already done much better than their predecessors.
Pfizer said in July it expects revenue from its COVID-19 vaccine to reach $33.5 billion this year, an estimate that could change depending on the impact of boosters or the possible expansion of shots to elementary school children.
That would be more than five times the $5.8 billion racked up last year by the world’s most lucrative vaccine _ Pfizer’s Prevnar13, which protects against pneumococcal disease.
It also would dwarf the $19.8 billion brought in last year by AbbVie’s rheumatoid arthritis treatment Humira, widely regarded as the world’s top-selling drug.
This bodes well for future vaccine development, noted Erik Gordon, a business professor at the University of Michigan.
Vaccines normally are nowhere near as profitable as treatments, Gordon said. But the success of the COVID-19 shots could draw more drugmakers and venture capitalists into the field.
“The vaccine business is more attractive, which, for those of us who are going to need vaccines, is good,” Gordon said.
© 2021 The Canadian Press
Vaccination wallet cards will no longer be accepted as transition period ends for B.C.'s COVID vaccine cards – CBC.ca
Starting Monday, British Columbians wanting to access restaurants and other recreational spaces will not be able to use their original proof of vaccination and will have to use the province’s vaccine card in digital or paper form.
Residents were able to use their original proof of vaccination, such as the wallet card given out at vaccination clinics, to access non-essential spaces until Sunday as part of a transition period to the province’s vaccine card program.
Currently, residents need to show proof of one dose of COVID-19 vaccine using the vaccine card. From Oct. 13, proof of two doses will be required to access non-essential spaces.
Some of the venues that require the vaccine card include:
- Indoor ticketed sporting events.
- Indoor concerts.
- Indoor theatre/dance/symphony events.
- Restaurants (indoor and patio dining).
- Night clubs.
- Movie theatres.
- Fitness centres/gyms (excluding youth recreational sport).
- Businesses offering indoor high-intensity group exercise activities.
- Organized indoor events (e.g., weddings, parties, conferences, meetings, workshops) with 50 or more people.
- Discretionary organized indoor group recreational classes and activities.
- Student housing on college and university campuses.
British Columbians can use their original proof of vaccination until Sept. 26. Starting Sept. 27, the B.C. Vaccine Card (digital or paper version) will be the only accepted form of proof. <a href=”https://t.co/lb8EsnvXqn”>pic.twitter.com/lb8EsnvXqn</a>
Cards are available through the provincial Health Gateway website. Once you’ve loaded the site, you need to enter your:
The vaccine card is a one-page file with your name, confirmed vaccination status and a QR code that will be scanned upon entry. You can take a screenshot of the card on your phone or print a paper copy.
Adults aged 19 and over will also need to show a government-issued piece of photo ID.
There are some exemptions to using B.C.’s vaccine card as proof of vaccination.
People from other Canadian provinces or territories must show an officially recognized vaccine record from their province or territory along with valid government photo ID.
International visitors must show proof of vaccination they used to enter Canada along with their passport.
Members of the Canadian Armed Forces can use their National Defence Canada COVID-19 vaccine record or card with their National Defence ID card.
COVID-19 booster shots could rake in billions for some vaccine makers – Global News
‘There’s energy in painting’: Imagine Pandosy Art Festival showcases local talent – Global News
Centurian jail for sale in Owen Sound offers spooky real estate investment – CTV News Barrie
Silver investment demand jumped 12% in 2019
Europe kicks off vaccination programs | All media content | DW | 27.12.2020 – Deutsche Welle
Iran anticipates renewed protests amid social media shutdown
Politics15 hours ago
Quebec undergoes a culture shift as ‘woke’ politics is redefined in the province – The Globe and Mail
Health19 hours ago
COVID-19 hospitalizations in Ottawa up slightly, ICU admissions down – Newstalk 1010 (iHeartRadio)
News15 hours ago
Coronavirus: What's happening in Canada and around the world on Sunday – CBC.ca
Business15 hours ago
Will China rescue the troubled property group Evergrande? | Inside Story – Al Jazeera English
Tech17 hours ago
‘Overwatch 2’ Sure Feels Like ‘Overwatch Patch v2.0’ So Far – Forbes
Sports15 hours ago
Blue Jays beat Twins; stay two back in AL wild-card race – TSN
Media3 hours ago
In the Elizabeth Holmes criminal case, the media is also on trial – CNN
News14 hours ago
Michael Kovrig and Michael Spavor have finally landed in Canada – CTV News